Wall Street analysts predict that Immunomedics, Inc. (NASDAQ:IMMU) will report ($0.13) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Immunomedics’ earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.21). Immunomedics reported earnings per share of ($0.22) in the same quarter last year, which would suggest a positive year over year growth rate of 40.9%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, May 9th.
On average, analysts expect that Immunomedics will report full year earnings of ($0.96) per share for the current year, with EPS estimates ranging from ($1.07) to ($0.85). For the next financial year, analysts forecast that the business will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.96) to $0.50. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Immunomedics.
Immunomedics (NASDAQ:IMMU) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.09). The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $0.90 million.
IMMU has been the subject of a number of recent research reports. Jefferies Group increased their target price on Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. BidaskClub upgraded Immunomedics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 25th. ValuEngine upgraded Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered Immunomedics from a “hold” rating to a “sell” rating in a research note on Saturday, February 17th. Finally, TheStreet upgraded Immunomedics from a “d” rating to a “c-” rating in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $19.00.
Immunomedics (IMMU) traded down $0.74 during mid-day trading on Wednesday, hitting $16.20. The stock had a trading volume of 2,768,856 shares, compared to its average volume of 2,317,745. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 1.20. Immunomedics has a fifty-two week low of $5.00 and a fifty-two week high of $18.93. The firm has a market capitalization of $2,470.00, a price-to-earnings ratio of -8.71 and a beta of 1.48.
In other news, Director David M. Goldenberg sold 20,000 shares of Immunomedics stock in a transaction that occurred on Wednesday, March 7th. The stock was sold at an average price of $17.50, for a total value of $350,000.00. Following the completion of the transaction, the director now owns 1,774,285 shares in the company, valued at approximately $31,049,987.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David M. Goldenberg sold 17,729 shares of Immunomedics stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $17.09, for a total value of $302,988.61. Following the completion of the transaction, the director now owns 1,774,285 shares of the company’s stock, valued at approximately $30,322,530.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 77,729 shares of company stock valued at $1,342,589. 14.80% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of IMMU. Raymond James Financial Services Advisors Inc. grew its position in shares of Immunomedics by 11.4% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 1,473 shares in the last quarter. Calton & Associates Inc. acquired a new position in shares of Immunomedics in the 4th quarter worth approximately $135,000. Xact Kapitalforvaltning AB acquired a new position in shares of Immunomedics in the 4th quarter worth approximately $193,000. Sapphire Star Partners LP bought a new stake in shares of Immunomedics in the 4th quarter worth approximately $323,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Immunomedics by 27.2% in the 3rd quarter. SG Americas Securities LLC now owns 26,350 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 5,631 shares during the last quarter. Institutional investors own 74.52% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Brokerages Expect Immunomedics, Inc. (IMMU) to Announce -$0.13 Earnings Per Share” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2018/03/14/brokerages-expect-immunomedics-inc-immu-to-announce-0-13-earnings-per-share.html.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.